Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570635 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
A Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors, sponsored by Exelixis.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT00570635 is a Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors that has completed, run by Exelixis. The registered enrollment target is 16 participants, below the 965-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00570635, a Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.
Conditions Studied
Interventions
- DRUG XL820
Study Locations (3)
California
- - Los Angeles
Illinois
- - Park Ridge
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570635
The ClinicalTrials.gov registry entry for NCT00570635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 965-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which XL820 is the first listed.
NCT00570635 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00570635 about?
NCT00570635 is a clinical study titled "A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib". The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.
What is the current status of trial NCT00570635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-12. Estimated completion is 2009-05.
What conditions does trial NCT00570635 study?
This clinical trial studies the following conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT00570635?
The interventions under investigation include: XL820 (DRUG).
Who is sponsoring clinical trial NCT00570635?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00570635 being conducted?
This trial has 3 study locations across California, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RECRUITING · Phase 3
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
RECRUITING
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
Explore more on PlainTrial
Gastrointestinal Neoplasms
All registered trials for this condition
Gastrointestinal Stromal Tumors
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.